glp 1 and visceral fat Still Have Stubborn After GLP1? We Have the Solution! Therapeutic Mechanisms and Clinical Effects
Description
Like the ADA, the AACE/ACE algorithm recommends intensification from monotherapy to dual therapy and beyond for patients not achieving glycemic goals after 3 months of therapy with a given antihyperglycemic regimen
Description This peptide is known for considerable amounts of weight loss and appetite suppression
Online assessment pathways, supported by clinician oversight and monitoring, are increasingly part of modern weight management services
PMID: 37952131
Importantly, both medications deliver double-digit weight loss averages, far beyond what has historically been possible with other treatments
